By Fineline Cube 
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced immediate withdrawal and product recall of TAZVERIK (tazemetostat), the EZH2 inhibitor licensed from Epizyme, Inc. (an Ipsen company), from mainland China, Hong Kong, and Macau. The action follows Ipsen’s global safety-driven withdrawal after the Phase 1b/3 SYMPHONY-1 trial in follicular lymphoma revealed secondary hematologic malignancies with risks outweighing potential benefits. HutchMed is discontinuing all active tazemetostat clinical trials and the NHSA has delisted the drug from provincial procurement platforms and the 2025 Innovative Drug List for Commercial Health Insurance effective immediately.
Withdrawal Overview
| Element | Detail |
|---|---|
| Product | TAZVERIK (tazemetostat) |
| Drug Class | EZH2 (enhancer of zeste homolog 2) methyltransferase inhibitor |
| Licensor | Epizyme, Inc. (Ipsen subsidiary) |
| Licensee | HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) |
| Markets Affected | U.S. (Ipsen voluntary withdrawal), China (HutchMed recall), Hong Kong, Macau |
| Indications Withdrawn | Follicular lymphoma (FL), epithelioid sarcoma (ES) |
| Trigger | SYMPHONY-1 trial safety signal (secondary hematologic malignancies) |
| Effective Date | 9 Mar 2026 |
Safety Signal & Clinical Context
| Trial | Design | Safety Finding | Risk-Benefit Assessment |
|---|---|---|---|
| SYMPHONY-1 | Phase 1b/3 | Tazemetostat + lenalidomide + rituximab (R²) vs. R² | Secondary hematologic malignancies observed |
| Conclusion | — | Risks outweigh potential benefits in follicular lymphoma | Ipsen initiated global withdrawal |
Mechanism Concern:
- EZH2 Inhibition: Epigenetic modulation may disrupt hematopoietic stem cell regulation
- Combination Risk: Tazemetostat + immunomodulatory (lenalidomide) + anti-CD20 potentially synergistic for myelosuppression/malignancy
Regulatory & Commercial Actions
| Jurisdiction | Action | Authority |
|---|---|---|
| United States | Voluntary withdrawal | Ipsen (manufacturer) |
| China Mainland | Product recall + trial discontinuation | HutchMed + NMPA coordination |
| Hong Kong/Macao | Product recall | HutchMed |
| Procurement | Delisting from all provincial platforms | NHSA (National Healthcare Security Administration) |
| Insurance | Removal from 2025 Innovative Drug List for Commercial Health Insurance | NHSA (per enterprise application) |
Financial Impact:
- HutchMed Revenue: TAZVERIK China sales immaterial to 2025 consolidated revenue ($548.5M total); minimal P&L impact
- Ipsen Write-down: Potential impairment on Epizyme acquisition ($247M in 2022)
- Clinical Trial Costs: HutchMed trial discontinuation costs anticipated Q1 2026
Strategic Implications
| Factor | Impact |
|---|---|
| HutchMed Pipeline | Loss of licensed oncology asset; reinforces strategy pivot to internal discovery (sovleplenib, fruquintinib) |
| China Regulatory Speed | NHSA same-day delisting demonstrates post-approval pharmacovigilance responsiveness |
| Epizyme/Ipsen Portfolio | EZH2 inhibitor class setback; raises questions about epigenetic therapy safety profile |
| Investor Sentiment | HCM shares may face short-term pressure on pipeline risk perception; mitigated by limited revenue exposure |
Forward-Looking Considerations
- HutchMed Response: Focus resources on internal pipeline assets (HSK31858, sovleplenib) and partnered programs with stronger safety profiles
- Class Effect: FDA/EMA may review other EZH2 inhibitors (valemetostat) for similar safety signals
- Lessons Learned: Importance of long-term safety monitoring in epigenetic modulators; combination trial design risk assessment
Forward‑Looking Statements
This brief contains forward‑looking statements regarding safety profile implications, regulatory responses, and strategic adjustments following the TAZVERIK withdrawal. Actual results may differ due to ongoing safety investigations, regulatory inquiries, and competitive dynamics in the oncology market.-Fineline Info & Tech